Literature DB >> 11848443

Catalytic antisense DNA molecules targeting Egr-1 inhibit neointima formation following permanent ligation of rat common carotid arteries.

Harry C Lowe1, Colin N Chesterman, Levon M Khachigian.   

Abstract

Animal models of neointima (NI) formation have proven useful in gaining insights into the mechanisms of restenosis after coronary angioplasty and stenting, but the events at a molecular level remain incompletely understood. Here, we describe a technically straightforward, rat model of NI formation, involving complete ligation of the common carotid artery and demonstrate the importance of the immediate-early gene and zinc finger transcription factor Egr-1 in this process. Acute cessation of common carotid blood flow by vessel ligation, was followed by the expression of Egr-1 in the arterial media within 3 h and NI formation proximal to the point of ligation at 18 days. Local delivery of catalytic oligodeoxynucleotides (ODN) targeting rat Egr-1 mRNA at the time of ligation reduced both Egr-1 expression and NI formation in this model. In contrast, a scrambled version of this ODN had no inhibitory effect. These studies demonstrate for the first time that arterial intimal thickening following artery ligation is critically-dependent on the activation of Egr-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11848443

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.

Authors:  Ravinay Bhindi; Roger G Fahmy; Harry C Lowe; Colin N Chesterman; Crispin R Dass; Murray J Cairns; Edward G Saravolac; Lun-Quan Sun; Levon M Khachigian
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

Review 2.  DNAzymes and cardiovascular disease.

Authors:  V L Benson; L M Khachigian; H C Lowe
Journal:  Br J Pharmacol       Date:  2008-05-05       Impact factor: 8.739

3.  c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins.

Authors:  Jun Ni; Alla Waldman; Levon M Khachigian
Journal:  J Biol Chem       Date:  2009-11-23       Impact factor: 5.157

Review 4.  Early growth response-1 in the pathogenesis of cardiovascular disease.

Authors:  Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2016-06-01       Impact factor: 4.599

5.  Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.

Authors:  Jun-ichi Suehiro; Takao Hamakubo; Tatsuhiko Kodama; William C Aird; Takashi Minami
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

6.  Electroporation-mediated delivery of catalytic oligodeoxynucleotides for manipulation of vascular gene expression.

Authors:  Elizabeth A Nunamaker; Hai-Ying Zhang; Yuichi Shirasawa; Joseph N Benoit; David A Dean
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-07-24       Impact factor: 4.733

7.  Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1.

Authors:  Ainslie Mitchell; Crispin R Dass; Lun-Quan Sun; Levon M Khachigian
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

8.  Deoxyribozymes: new therapeutics to treat central nervous system disorders.

Authors:  Barbara Grimpe
Journal:  Front Mol Neurosci       Date:  2011-09-23       Impact factor: 5.639

9.  IL-1beta signals through the EGF receptor and activates Egr-1 through MMP-ADAM.

Authors:  Estella Sanchez-Guerrero; Elya Chen; Maaike Kockx; Si-Wei An; Beng H Chong; Levon M Khachigian
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Delivery system for DNAzymes using arginine-modified hydroxyapatite nanoparticles for therapeutic application in a nasopharyngeal carcinoma model.

Authors:  Yan Chen; Lifang Yang; Suping Huang; Zhi Li; Lu Zhang; Jiang He; Zhijie Xu; Liyu Liu; Ya Cao; Lunquan Sun
Journal:  Int J Nanomedicine       Date:  2013-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.